Neuromyelitis optica: A review

Seminars in Ophthalmology

Volumn 26, Issue 4-5, 2011, Pages 337-341

  Thornton, Ivey L ^a   Rizzo, Joseph F ^a   Cestari, Dean M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti NMO Ig G; Aquaporin 4; Devic's disease

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; MITOXANTRONE; PREDNISONE;

CEREBROSPINAL FLUID; DEMYELINATION; DIAGNOSTIC PROCEDURE; GRAY MATTER; HUMAN; IMMUNOPATHOLOGY; MYELOOPTIC NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SEROLOGY; WHITE MATTER;

AUTOIMMUNE DISEASES; HUMANS; NEUROMYELITIS OPTICA;

EID: 80053549564     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.588667     Document Type: Review

References (32)

1. Allbutt TC. On the ophthalmoscopic signs of spinal disease. Lancet. 1870;1:76-8
2. Erb W. Ueber das zusammenvorkommen von Neuritis optica und Myelitis subacuta. Arch Psychiatrie Neureu. 1880;10:146-57
3. Devic E. Myelite subaigue compliquee de neurite optique. Bull Med. 1894;8:1033-034
4. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53;1107-118
5. Goulden C. Optic neuritis and myelitis. Ophthalmic Rev. 1914; 34:193-209
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004;364:2106-2112 (Pubitemid 39626806)
7. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-77 (Pubitemid 41186945)
8. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology. 2001;56:507-14 (Pubitemid 32172877)
9. Kuroiwa Y, Igata A, Itahara K, et al. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1084 cases. Neurology. 1975;25:845-851
10. Cabera-Gomez JA, kurtzke JF, Gonzalez-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256:35-44
11. Nandhagopal R, AL-Asmi A, Gujjar, AR. Neuromyelitis optica: An overview. Postgrad Med J. 2010;86:153-159
12. Wingerchuk M, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003;60:848-53 (Pubitemid 36297372)
13. Popescu BF, Lennon VA, Parisi JE. Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications. Neurology. 2011; Mar 2
14. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390-96
15. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65;1479-482 (Pubitemid 41552787)
16. Galetta SL, Bennett J. Neuromyelitis optica is a variant of multiple sclerosis. Arch Neurol. 2007;64:901-03 (Pubitemid 46919850)
17. Mandler RN, Ahmed W, Dencoff JE. 1998. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219-220
18. Goodin DS, Frohman EM, Garmany GP, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-78 (Pubitemid 34086933)
19. Cree B, Goodin DS, Hauser SL. Neuromyelitis optica. Seminars in Neuro. 2002;22:105-22 (Pubitemid 35425276)
20. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica Neurology. 2006;66:1485-489 (Pubitemid 43958540)
21. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin 4 antibody is involved in the pathogenesis of NMO: A study on antibody titer. Brain. 2007(Pt 5);130:1235-243 (Pubitemid 47355956)
22. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin- 4 in the long-term course of neuromyelitis optic. Brain. 2008;131(Pt 11):3072-080
23. Weinstock-Guttman B, Miller C, Yeh E, et al. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler. 2008;14:1061-067
24. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60:382-87 (Pubitemid 26118744)
25. Jarius S, Franciotta D, Bergamaschi R, et al . Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med. 2010;48(5):659-63
26. Stansbury FC. Neuromyelitis optica (Devic's disease). Presentation of five cases with pathological study and review of the literature. Arch Ophthalmol. 1949;42:292-335, 465-501
27. Scott GI. Neuromyelitis optica. Am J Ophthalmol. 1952;35:755-764
28. Mandler RN, Davis L.E., Jeffery DR, Kornfeld MK. Devic's neuromyelitis optica: A clinicopathological study of 8 patients. Ann Neurol. 1993;34:162-168 (Pubitemid 23223043)
29. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-461 (Pubitemid 34755161)
30. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol. 2008;255:163-70
31. Kim S.H., Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2010
32. Awad A, Stuve O. Cyclophosphamide in multiple sclerosis: Scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord. 2009;2(6):50-61